EPRX
$7.58
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with s...
Recent News
Eupraxia Reports Positive Six-Month Data From Eosinophilic Esophagitis Trial
Eupraxia Pharmaceuticals (EPRX.TO) Tuesday reported "positive data" from patients in the two highest
Eupraxia Pharmaceuticals Q4 Loss Widens
Eupraxia Pharmaceuticals (EPRX.TO) overnight Thursday reported a wider fourth-quarter net loss. T
Eupraxia Pharmaceuticals Closes US$63.2M Public Offering Including Full Exercise of Underwriter Option
Eupraxia Pharmaceuticals (EPRX.TO, EPRX) was at last look up 4% in late Friday afternoon trade in Ca
Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering
Eupraxia Pharmaceuticals (EPRX.TO, EPRX) on Thursday announced the pricing of its previously announc
Here's Why We're Not At All Concerned With Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...